ZELTIA GROUP


Zeltia Group: Report at 31 March 2005

MADRID, April 28/PRNewswire/ --

PharmaMar:


- Zalypsis: this is PharmaMar's fifth compound to reach clinical development.


- Aplidin: commenced Phase II studies on prostate and bladder cancer.


- Yondelis: pivotal Phase III studies commenced on ovarian cancer patients.

NeuroPharma:


- Presented pre-clinical data at the 7th International Conference on Alzheimer's and Parkinson's Disease.

Other:


- Investment in R&D amounted to 8.9 million euro in the first quarter.


- Group short- and long-term debt was similar to December 2004.


- Net cash consumption was 3.8 million euro in the first quarter.

Source: Zeltia Group

Isabel Lozano, CEO, PHARMAMAR, S.A., C/ Reyes, 1.Colmenar Viejo, Madrid, Telephone +34-91-846-60-00; Catherine Moukheibir, Head of Capital Market Strategy, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00; Ma. Luisa de Francia, CFO, ZELTIA, S.A., José Abascal, 2. Madrid, Telephone +34-91-444-45-00

28 apr 05 10:45